The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
Open accessPublished version of a preprint
Abstract
Background: Identifying a meaningful progression metric for Parkinson’s disease (PD) that reflects heterogeneity remains a challenge. Objective: To assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones. Methods: Using data from the Parkinson’s Progression Markers Initiative (PPMI) de novo PD cohort, we monitored 25 milestones across six domains (“walking and balance”; “motor complications”; “cognition”; “autonomic dysfunction”; “functional dependence”; “activities of daily living”). Milestones were intended to be severe enough to reflect meaningful disability. We assessed the proportion of participants reaching any milestone; evaluated which occurred most frequently; and conducted a time-to-first-event analysis exploring whether baseline characteristics were associated with progression. Results: Half of participants reached at least one milestone within five years. Milestones within the cognitive, functional dependence, and autonomic dysfunction domains were reached most often. Among participants who reached a milestone at an annual follow-up visit and remained active in the study, 82% continued to meet criteria for any milestone at one or more subsequent annual visits and 55% did so at the next annual visit. In multivariable analysis, baseline features predicting faster time to reaching a milestone included age ( p < 0.0001), greater MDS-UPDRS total scores ( p < 0.0001), higher GDS-15 depression scores ( p = 0.0341), lower dopamine transporter binding ( p = 0.0043), and lower CSF total α-synuclein levels ( p = 0.0030). Symptomatic treatment was not significantly associated with reaching a milestone ( p = 0.1639). Conclusion: Clinically relevant milestones occur frequently, even in early PD. Milestones were significantly associated with baseline clinical and biological markers, but not with symptomatic treatment. Further studies are necessary to validate these results, further assess the stability of milestones, and explore translating them into an outcome measure suitable for observational and therapeutic studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large-scale initiatives such as the UK Biobank (including 100 000 participants) (Sudlow et al., 2015), ADNI (Mueller et al., 2005), and Parkinson’s Progression Markers Initiative (PPMI) (Brumm et al., 2023) exemplify progress in neuroimaging diversity; however, significant disparities persist in racial, socioeconomic, and rare dementia representations”
From Multimodal neuroimaging and AI integration in cognitive disorders: advances, challenges, and future directions for precision medicine (2026) · cites this paper as Brumm et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“Outcomes measures comprised by a composite of clinically relevant events have been applied in other areas of medicine—including cancer [36], cardiology [37], nephrology [38], and stroke [39]—and have been acceptable to regulators [40].”
Adams, J. L., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W., Goldenthal, S., Biglan, K. M., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,171
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Benardete, E. A., & Nair, A. K. (2015) · Cerebrovascular Diseases Extra · doi:10.1159/000370060 · Cited by 2,546
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Self-citationThe Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study
Aarsland, D., Andersen, K., Larsen, J. P., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,401
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
survminer: Drawing Survival Curves using 'ggplot2'
Kassambara, A., Kosinski, M., & Biecek, P. (2016) · CRAN: Contributed Packages · doi:10.32614/cran.package.survminer · Cited by 1,177
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
Williams-Gray, C. H., Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2007) · Brain · doi:10.1093/brain/awm111 · Cited by 934
Stebbins, G. T., Goetz, C. G., Burn, D. J., Jankovic, J., Khoo, T. K., & Tilley, B. C. (2013) · Movement Disorders · doi:10.1002/mds.25383 · Cited by 932
The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study
Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2004) · Brain · doi:10.1093/brain/awh067 · Cited by 688
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Williams-Gray, C. H., Mason, S. L., Evans, J. R., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305277 · Cited by 681
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell‐Garcia, C., Simuni, T., Jennings, D., Tanner, C. M., Trojanowski, J. Q., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.644 · Cited by 671
Self-citationDJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Self-citationPeto, V., Jenkinson, C., & Fitzpatrick, R. (1998) · Journal of Neurology · doi:10.1007/pl00007730 · Cited by 576
Modelling recurrent events: a tutorial for analysis in epidemiology
Amorim, L. D., & Cai, J. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyu222 · Cited by 564 · cited 1×
“Alternative approaches that may increase study power include recurrent event models [56, 57] or repeated-measures analysis of an ordinal or continuous “score” reflecting the sum of multiple milestones/domains.”
Methods for interval-censored data
Lindsey, J. C., & Ryan, L. M. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980130)17:2<219::aid-sim735>3.0.co;2-o · Cited by 374
Kang, J.-H. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3861 · Cited by 367
Self-citationCognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub, D., Simuni, T., Caspell‐Garcia, C., Coffey, C., Lasch, S., Siderowf, A., Aarsland, D., Barone, P., Burn, D., Chahine, L. M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26170 · Cited by 305
Self-citationThe association of incident dementia with mortality in PD
Levy, G., Tang, M.-X., Louis, E. D., Côté, L. J., Alfaro, B., Mejia, H., Stern, Y., & Marder, K. (2002) · Neurology · doi:10.1212/01.wnl.0000036610.36834.e0 · Cited by 297
Martinez-Martin, P., Rodriguez-Blazquez, C., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., Chade, A., Garretto, N., Gershanik, O., Kurtis, M. M., Martinez-Castrillo, J. C., et al. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6624-1 · Cited by 252
Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease
De Pablo-Fernandez, E., Tur, C., Revesz, T., Lees, A. J., Holton, J. L., & Warner, T. T. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1125 · Cited by 235
The natural history of Parkinson’s disease
Poewe, W. (2006) · Journal of Neurology · doi:10.1007/s00415-006-7002-7 · Cited by 224
Prognosis of Parkinson Disease: Risk of Dementia and Mortality: The Rotterdam Study
de Lau, L. M. L., Schipper, C. M. A., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2005) · Archives of Neurology · doi:10.1001/archneur.62.8.1265 · Cited by 211
Kieburtz, K., Tilley, B. C., Elm, J. J., Babcock, D., Hauser, R., Ross, G. W., Augustine, A. H., Augustine, E. U., Aminoff, M. J., Bodis-Wollner, I. G., et al. (2015) · JAMA · doi:10.1001/jama.2015.120 · Cited by 207
Self-citationSimuni, T., Siderowf, A., Lasch, S., Coffey, C. S., Caspell‐Garcia, C., Jennings, D., Tanner, C. M., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., et al. (2018) · Movement Disorders · doi:10.1002/mds.27361 · Cited by 201
Self-citationIsradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial
(2020) · Annals of Internal Medicine · doi:10.7326/m19-2534 · Cited by 189
The Parkinson Study Group SURE-PD3 Investigators, Bluett, B., Togasaki, D. M., Mihaila, D., Evatt, M., Rezak, M., Jain, S., Schwarzschild, M. A., Ascherio, A., Casaceli, C., et al. (2021) · JAMA · doi:10.1001/jama.2021.10207 · Cited by 165
Self-citationTotal CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 163
Self-citationCaspell-Garcia, C., Simuni, T., Tosun-Turgut, D., Wu, I.-W., Zhang, Y., Nalls, M., Singleton, A., Shaw, L. A., Kang, J.-H., Trojanowski, J. Q., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0175674 · Cited by 159
Self-citationLongitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease
Mollenhauer, B., Caspell‐Garcia, C., Coffey, C. S., Taylor, P., Singleton, A. B., Shaw, L. M. J., Trojanowski, J. Q., Frasier, M. A., Simuni, T., Iranzo, Á., et al. (2019) · Movement Disorders · doi:10.1002/mds.27806 · Cited by 159
Self-citationTutorial on methods for interval-censored data and their implementation in R
Melis, G. G., Calle, M. L., Oller, R., & Langohr, K. (2009) · Statistical Modelling · doi:10.1177/1471082x0900900402 · Cited by 133
Composite End Points in Clinical Research
Armstrong, P. W., & Westerhout, C. M. (2017) · Circulation · doi:10.1161/circulationaha.117.026229 · Cited by 132
Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson’s Disease
Ravina, B., Marek, K., Eberly, S., Oakes, D., Kurlan, R., Ascherio, A., Beal, F. M., Beck, J., Flagg, E., Galpern, W., et al. (2012) · Movement Disorders · doi:10.1002/mds.25157 · Cited by 130
Self-citationEvolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
Irwin, D. J., Fedler, J. K., Coffey, C. S., Caspell‐Garcia, C., Kang, J., Simuni, T., Foroud, T., Toga, A. W., Tanner, C. M., Kieburtz, K. D., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25811 · Cited by 115
Self-citationCaslake, R., Taylor, K. S. M., SCOTT, N. W., Gordon, J. C., Harris, C., Wilde, K., Murray, A. D., & Counsell, C. E. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.01.014 · Cited by 108
Simuni, T., Brumm, M. C., Uribe, L., Caspell‐Garcia, C., Coffey, C. S., Siderowf, A. D., Alcalay, R. N., Trojanowski, J. Q., Shaw, L. M. J., Seibyl, J. P., et al. (2020) · Movement Disorders · doi:10.1002/mds.27989 · Cited by 88
Self-citationNeuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Weintraub, D. A., Caspell‐Garcia, C., Simuni, T., Cho, H. R., Coffey, C. S., Aarsland, D., Alcalay, R. N., Barrett, M. J., Chahine, L. M., Eberling, J. L., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51022 · Cited by 87
Self-citationA user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations
Mollenhauer, B., Batrla, R., El‐Agnaf, O. M. A., Galasko, D. R., Lashuel, H. A., Merchant, K., Shaw, L. M., Selkoe, D. J., Umek, R. M., Vanderstichele, H., et al. (2017) · Movement Disorders · doi:10.1002/mds.27090 · Cited by 75
Self-citationComparative responsiveness of Parkinson's disease scales to change over time
Schrag, A. E., Spottke, A. E., Quinn, N. P., & Dodel, R. C. (2009) · Movement Disorders · doi:10.1002/mds.22438 · Cited by 71
Elm, J. J., & The NINDS NET‐PD Investigators (2012) · Movement Disorders · doi:10.1002/mds.25175 · Cited by 65
Parkinson’s disease clinical milestones and mortality
González, M. C., Dalen, I., Maple‐Grødem, J., Tysnes, O., & Alves, G. W. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00320-z · Cited by 65
Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease
McDermott, M., Jankovic, J. J., Carter, J., Fahn, S., Gauthier, S. G., Goetz, C. G., Golbe, L. I., Koller, W. C., Lang, A. E., Olanow, C. W., et al. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540300037010 · Cited by 61
Self-citationMartin, G. P., McDonald, K. R., Allsop, D., Diggle, P. J., & Leroi, I. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09538-z · Cited by 53
Clinical Neuromythology IX — Pyramid sale in the bucket shop: DATATOP bottoms out
Landau, W. M. (1990) · Neurology · doi:10.1212/wnl.40.9.1337 · Cited by 51
Use of composite endpoints in thrombolysis trials of acute myocardial infarction
Braunwald, E., Cannon, C. P., & McCabe, C. H. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90101-h · Cited by 47
Using global statistical tests in long‐term Parkinson's disease clinical trials
Huang, P., Goetz, C. G., Woolson, R. F., Tilley, B. C., Kerr, D. A., Palesch, Y. Y., Elm, J. J., Ravina, B. M., Bergmann, K. J., & Kieburtz, K. D. (2009) · Movement Disorders · doi:10.1002/mds.22645 · Cited by 43
Self-citationDesign of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)
Schneider, R. B., Omberg, L., Macklin, E. A., Daeschler, M., Bataille, L., Anthwal, S., Myers, T. L., Baloga, E., Duquette, S., Snyder, P., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51236 · Cited by 31
Self-citationPredictors of time to initiation of symptomatic therapy in early Parkinson's disease
Simuni, T., Long, J. D., Caspell‐Garcia, C., Coffey, C. S., Lasch, S., Tanner, C. M., Jennings, D. L., Kieburtz, K. D., MAREK, K. L., & the PPMI Investigators (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.317 · Cited by 31
Self-citationClinical milestones in Parkinson's disease: Past, present, and future
Marsili, L., & Mahajan, A. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120082 · Cited by 27
Ozga, A., & Rauch, G. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01511-1 · Cited by 12
Merola, A., & Coon, E. A. (2020) · Clinical Autonomic Research · doi:10.1007/s10286-020-00684-3 · Cited by 6
Research works printed but not linked: 5
- Fahn S, 1987, Recent Dev Parkinsons Dis, 2, 153
- Poewe W, 2006, J Neurol, 253, VII2
- McDermott MP, 1995, Arch Neurol, 52, 565
- Kang JH, 2013, JAMA Neurol, 70, 1277
- Food and Drug Administration, 2017, Multiple endpoints in clinical trials: Guidance for industry
Cited by
AI-powered integration of multimodal imaging in precision medicine for neuropsychiatric disorders
Huang, W., & Shu, N. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102132 · Cited by 85
Dam, T., Pagano, G., Brumm, M. C., Gochanour, C., Poston, K. L., Weintraub, D. A., Chahine, L. M., Coffey, C. S., Tanner, C. M., Kopil, C., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00789-w · Cited by 56
Self-citationLoss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson's disease
Espay, A. J., & Lees, A. J. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106077 · Cited by 51
Suárez, P. R., del Campo, N., Bénatru, I., Moreau, C., Desjardins, C., Sánchez‐Ferro, Á., & Fabbri, M. (2024) · Movement Disorders · doi:10.1002/mds.30056 · Cited by 46
Iqbal, M. K., Khan, B., Hifsa, H., YuXuan, G., Mujahid, M., Kiyani, M. M., Khan, H. R., & Bashir, S. (2024) · ACS Omega · doi:10.1021/acsomega.4c06546 · Cited by 38
Metadata
- Authors
- Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., Merchant, K., Arnedo, V., Hutten, S. J., O’Grady, A. N., Poston, K. L., Tanner, C. M., Weintraub, D., Kieburtz, K., Marek, K., Coffey, C. S., & Initiative, O. B. O. T. P. P. M.
- Affiliations
- University of Iowa (US)
- University of Pennsylvania (US)
- Northwestern University (US)
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
- University of Pittsburgh (US)
- Universitätsmedizin Göttingen (DE)
- Indiana University Indianapolis (US)
- University of California San Diego (US)
- Michael J. Fox Foundation (US)
- Stanford Medicine (US)
- San Francisco VA Medical Center (US)
- Philadelphia VA Medical Center (US)
- University of Rochester Medicine (US)
- Institute for Neurodegenerative Disorders (US)
- Corresponding author
- Brumm, Michael C.
- ORCID
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2023-07-12
- Volume
- 13
- Issue
- 6
- Pages
- 899-916
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC10578214
- OpenAlex
- W4384301272
- Cited by
- 70
- References
- 58
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 17 · 2023: 1
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- Michael J. Fox Foundation for Parkinson's Research
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Biogen
- CHDI Foundation
- Teva Pharmaceutical Industries
- Celgene
- University of Pennsylvania
- University of Pittsburgh
- International Parkinson and Movement Disorder Society
- Demensförbundet
- Jazz Pharmaceuticals
- Parkinson's Foundation
- Acorda Therapeutics
- Neurocrine Biosciences
- Verily Life Sciences
- Voyager Therapeutics
- Deutsche Forschungsgemeinschaft
- Eisai
- Servier
- H. Lundbeck A/S
- Sun Pharma
- Deutsche Parkinson Vereinigung
- National Institutes of Health
- Genentech
- Allergan
- Sanofi Genzyme
- Avid Radiopharmaceuticals
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease progression, Parkinson's Progression Markers Initiative, de novo Parkinson's disease, predictors of progression, motor complications, cognitive impairment, functional dependence, autonomic dysfunction, activities of daily living, depression, dopamine transporter imaging, MDS-UPDRS, symptomatic treatment, disability
- MeSH terms
- Cognition, Humans, Parkinson Disease, Biomarkers, Disease Progression, Primary Dysautonomias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.